Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension

Clinical Cardiology

Volumn 37, Issue 6, 2014, Pages 365-370

  Zheng, Ya Guo ^a   Yang, Tao ^a   He, Jian Guo ^a   Chen, Guo ^a   Liu, Zhi Hong ^a   Xiong, Chang Ming ^a   Gu, Qing ^a   Ni, Xin Hai ^a   Zhao, Zhi Hui ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR; SOLUBLE SUPPRESSION OF TUMORIGENICITY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; HEART INDEX; HEMODYNAMICS; HUMAN; LABORATORY TEST; LUNG VASCULAR RESISTANCE; MALE; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; CLINICAL TRIAL; HYPERTENSION, PULMONARY; PROCEDURES;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-1;

EID: 84902543835     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22262     Document Type: Article

References (34)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2009; 30: 2493-2537.
2. Ranu H, Smith K, Nimako K, et al. A retrospective review to evaluate the safety of right heart catheterization via the internal jugular vein in the assessment of pulmonary hypertension. Clin Cardiol. 2010; 33: 303-306.
3. Schwaiblmair M, Faul C, von Scheidt W, et al. Detection of exercise-induced pulmonary arterial hypertension by cardiopulmonary exercise testing. Clin Cardiol. 2012; 35: 548-553.
4. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation. 2003; 108: 844-848.
5. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000; 102: 865-870.
6. Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med. 1999; 160: 487-492.
7. Renard S, Paulin R, Breuils-Bonnet S, et al. Pim-1: a new biomarker in pulmonary arterial hypertension. Pulm Circ. 2013; 3: 74-81.
8. Santos M, Reis A, Gonçalves F, et al. Adiponectin levels are elevated in patients with pulmonary arterial hypertension. Clin Cardiol. 2014; 37: 21-25.
9. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Investig. 2007; 117: 1538-1549.
10. Kakkar R, Lee RT,. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008; 7: 827-840.
11. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106: 2961-2966.
12. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004; 109: 2186-2190.
13. Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010; 55: 243-250.
14. Kohli P, Bonaca MP, Kakkar R, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012; 58: 257-266.
15. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011; 4: 180-187.
16. Rehman SU, Mueller T, Januzzi JL,. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008; 52: 1458-1465.
17. Shah RV, Chen-Tournoux AA, Picard MH, et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail. 2009; 2: 311-319.
18. Daniels LB, Clopton P, Iqbal N, et al. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J. 2010; 160: 721-728.
19. Agoston-Coldea L, Lupu S, Hicea S, et al. Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction. Biomark Med. 2014; 8: 11-18.
20. Chida A, Sato H, Shintani M, et al. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Circ J. 2014; 78: 436-442.
21. Carlomagno G, Messalli G, Melillo RM, et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol. 2013; 168: 1545-1547.
22. Mueller T, Dieplinger B,. The Presage ST2 assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Exp Rev Mol Diagn. 2013; 13: 13-30.
23. D'Alto M, Romeo E, Argiento P, et al. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. Heart. 2010; 96: 1475-1479.
24. Minai OA, Gudavalli R, Mummadi S, et al. Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012; 185: 400-408.
25. Hoeper MM, Maier R, Tongers J, et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med. 1999; 160: 535-541.
26. Zhang HL, Liu ZH, Wang Y, et al. Acute responses to inhalation of iloprost in patients with pulmonary hypertension. Chin Med J (Engl). 2012; 125: 2826-2831.
27. Dieplinger B, Januzzi JL Jr, Steinmair M, et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chim Acta. 2009; 409: 33-40.
28. Zilinski JL, Shah RV, Gaggin HK, et al. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care. 2012; 16: R135.
29. Liew FY, Pitman NI, McInnes IB,. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010; 10: 103-110.
30. Bogaard HJ, Abe K, Vonk Noordegraaf A, et al. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009; 135: 794-804.
31. Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008; 52: 2166-2174.
32. Shao D, Perros F, Humbert M, et al. Is there a role for IL-33 in the pathogenesis of pulmonary arterial hypertension? Thorax. 2010; 65: A70.
33. Mahmood A, McSharry C, Xu D, et al. The role of ST2 in a model of pulmonary hypertension. Thorax. 2010; 65: A70-A71.
34. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369: 809-818.